**Introduction**

Pure small cell carcinoma of the esophagus is very rare [1]. The author reports herein primary small cell carcinoma of the esophagus with an emphasis on KIT and PDGFRA genes and their products (KIT and PDGFRA), which are transmembranous tyrosine kinases involved in tumorigenesis of several neoplasms including gastrointestinal stromal tumor (GIST) [2].

**Case report**

A 72-year-old man was admitted to our hospital because of dysphagia, and endoscopy showed a tumor in the esophagus (Figure 1A). A biopsy of the esophageal tumor showed a small cell carcinoma consisting of malignant small cells with very hyperchromatic nuclei and inconspicuous nucleoli and without any differentiations. An immunohistochemical study revealed positive reaction for cytokeratin (Dako, Glostrup, Denmark), KIT, PDGFRA, synaptophysin, p53 protein, and CD56, and negative reaction for chromogranin, CD45, CD20, CD3, and CD30. The Ki-67 labeling was 95%. A molecular genetic analysis showed no mutations of KIT and PDGFRA genes. The patient underwent radiation (50 Gray) and chemotherapy (cisplatin, 5 courses), but he developed liver and bone metastases and died of systemic carcinomatosis five months after the initial presentation.

**Keywords:** Esophagus, small cell carcinoma, KIT, PDGFRA

---

**Case Report**

**KIT and PDGFRA in esophageal pure small cell carcinoma**

Tadashi Terada

Department of Pathology, Shizuoka City Shimizu Hospital, Shizuoka, Japan

Received September 1, 2011; accepted October 11, 2011; Epub October 16, 2011; published October 31, 2011

**Abstract:** The author herein reports a very rare case of pure small cell carcinoma of the esophagus with an emphasis on KIT and PDGFRA. A 72-year-old man was admitted to our hospital because of dysphagia, and endoscopy showed a tumor in the esophagus. A biopsy of the esophageal tumor showed a small cell carcinoma consisting of malignant small cells with very hyperchromatic nuclei and inconspicuous nucleoli and without any differentiations. An immunohistochemical study revealed positive reaction for cytokeratin (Dako, Glostrup, Denmark), KIT, PDGFRA, synaptophysin, p53 protein, and CD56, and negative reaction for chromogranin, CD45, CD20, CD3, and CD30. The Ki-67 labeling was 95%. A molecular genetic analysis showed no mutations of KIT and PDGFRA genes. The patient underwent radiation (50 Gray) and chemotherapy (cisplatin, 5 courses), but he developed liver and bone metastases and died of systemic carcinomatosis five months after the initial presentation.

**Keywords:** Esophagus, small cell carcinoma, KIT, PDGFRA
chemotherapy (cisplatin, 5 courses), but he developed liver and bone metastases and died of systemic carcinomatosis five months after the initial presentation. Autopsy was not performed.

Discussion

Small cell carcinoma can occur in any organ, but the vast majority develops in the lung. Small
cell carcinoma is a very aggressive tumor and the prognosis is very poor, as in the present case. The present case is the first report of esophageal pure small cell carcinoma that examined KIT and PDGFRA proteins and genes. The present case showed KIT and PDGFRA expression. KIT has been reported to be expressed in 30-80% of small cell lung carcinoma \[11,12\]. The present case shows that esophageal small cell carcinoma also expresses KIT protein. No studies of PDGFRA protein have been reported in small cell carcinoma. The present study showed PDGFRA expression, suggesting that small cell carcinoma of the esophagus expresses this oncoprotein. The present case did not show mutations of KIT and PDGFRA genes. Most reports of small cell lung carcinoma have shown no mutations in KIT genes \[11\], except for Boldrini et al. \[12\] who found five mutations in 60 small cell lung carcinomas. On the other hand, Sihto et al. \[11\] showed no KIT mutations in 31 small cell lung carcinomas. More studies of KIT mutations remain to be performed in small cell carcinoma. With regard to PDGFRA mutations, Sihto et al. \[11\] showed no mutations in 31 small cell lung carcinomas. They insisted that KIT expression in small cell lung carcinoma is due not to KIT gene mutations but to KIT gene amplification \[11\].

Among many KIT-positive tumors, GIST is representative \[1\]. It is thought that GIST arises from interstitial cell of Cajal, a pacemaker neuronal cell that normally expresses KIT protein \[1\]. In contrast, small cell carcinoma is an undifferentiated carcinoma with neuroendocrine phenotype. The original cells of small cell carcinoma is unknown. Recently, Blumming et al. \[13\] found that GIST expresses synaptic vesicle proteins, and suggested that GIST has endocrine features. Therefore, it is suggested that there may be an association between GIST and small cell carcinoma in that both have neuroendocrine features.

Several studies in GIST have revealed that there are minute subclinical microGISTs or “GIST tumorlets” in the gastrointestinal tract \[14-16\]. The incidence of these is about 20%, and these are considered as GIST precursors. Frequent KIT mutations (about 46%) and occasional PDGFRA mutations (about 4%) are present in these “GIST tumorlets” \[14\]. However, these “GIST tumorlets” do not always develop into clinical GIST. Other genetic events are necessary for the development of clinical GIST. In contrast, little is known about the precursor lesions in small cell carcinoma.

Recently, phosphorylation (activation) status of KIT and PDGFRA has been studies \[17, 18\]. This is particularly important in KIT mutation-negative tumors as in the present case. KIT kinase activation and downstream signaling proteins leading to tumorigenesis have been studied, but little is known as yet. Protein kinase C-theta and PI3-kinase/AKT are activated in imatinib-resistant GIST \[17, 18, 19\], and analyses of these KIT signaling molecules may be important in the treatment of GIST. Such studies are not performed in small cell carcinoma. In the present study, the author could not investi-
gate these molecules, because no relevant antibodies were available. KIT tyrosine kinase activity and KIT signaling abnormalities in small cell carcinoma remain to be elucidated.

In summary, the author reported a very rare case of esophageal small cell carcinoma with KIT and PDGFRA expressions but without KIT and PDGFRA mutations.

Conflict of interest

The author declares no conflict of interest.

Address correspondence to: Tadashi Terada, MD, PhD, Department of Pathology, Shizuoka City Shimizu Hospital, Miyakami 1231 Shimizu-Ku, Shizuoka 424-8636, Japan. Tel: 81-54-336-1111; Fax: 81-54-336-1315; E-mail: piyo0111jp@yahoo.co.jp

References


